Influence of MTHFR 1298A→C polymorphism on response to transarterial chemoembolization in primary hepatocellular carcinoma: A pilot study

2011 ◽  
Author(s):  
Lian-Hua Cui ◽  
Xiao-Wen Xu ◽  
Zhen-Yu Quan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Transarterial Chemoembolization ◽  
Primary Hepatocellular Carcinoma

The pilot study: a novel transarterial chemoembolization using degradable starch microspheres for hepatocellular carcinoma

Kanzo ◽  
2008 ◽  
Vol 49 (1) ◽  
pp. 25-27 ◽  
Author(s):  
Takahiro Yamasaki ◽  
Issei Saeki ◽  
Yohei Harima ◽  
Kohsuke Okita ◽  
Makoto Segawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Transarterial Chemoembolization ◽  
Degradable Starch Microspheres

scholarly journals DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study

Gut and Liver ◽  
2013 ◽  
Vol 7 (1) ◽  
pp. 89-95 ◽  
Author(s):  
Do Seon Song ◽  
Jong Young Choi ◽  
Sun Hong Yoo ◽  
Hee Yeon Kim ◽  
Myeong Jun Song ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Transarterial Chemoembolization

scholarly journals Clinical Characteristics of Transarterial Chemoembolization in Treatment of Primary Hepatocellular Carcinoma Complicated With Respiratory Distress Syndrome

2020 ◽  
Vol 19 ◽  
pp. 153303382097067
Author(s):  
Ji-Yin Ruan ◽  
Jia-Tian Lin ◽  
Yu Xiong ◽  
Zai-Zhong Chen ◽  
Jun-Hui Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Hormone Therapy ◽  
Transarterial Chemoembolization ◽  
Clinical Characteristics ◽  
Pathogenic Bacteria ◽  
Distress Syndrome ◽  
Lateral Lobe ◽  
Primary Hepatocellular Carcinoma

Objective: The present study aims to analyze the clinical characteristics and etiology of transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC) complicated with acute respiratory distress syndrome (ARDS), in order to improve the early diagnosis rate and cure rate. Methods: A total of 816 patients with primary HCC received 2,200 TACE treatments from January 2014 to May 2018. Among these patients, 6 patients developed ARDS after TACE. The clinical data, lesion characteristics, laboratory tests, treatment process and prognosis of 6 patients were retrospectively analyzed. Results: The longest lesion diameter ranged within 5.0-10.2 cm (mean: 6.6 cm) in the 6 patients with primary HCC. Among these patients, 4 patients had lesions mainly located in the left lateral lobe of the liver, while 5 patients had no hepatic arteriovenous fistula detected before TACE. Nedaplatin, epirubicin and iodinated oil suspension chemoembolization were used in all 6 patients during TACE, and all of them experienced ARDS symptoms within 24-48 hours after TACE. However, no clear pathogenic bacteria were incubated in the sputum culture after the onset of the disease. Diffused exudative changes of both lungs were found in the chest X-ray, and the oxygenation index (PaO2/FiO2) was within 100-300 mmHg. The symptoms of 6 patients improved after 3-6 days of hormone therapy. Conclusion: In this study, we found that although the incidence of ARDS after TACE was low in the treatment for HCC, the symptoms after onset were serious, and the early hormone therapy may be beneficial to improve the prognosis and reduce mortality. Further research with larger samples is still needed to confirm the pathogenesis of ARDS after TACE in the treatment for HCC.

Sign in / Sign up

Export Citation Format

Share Document